 SAN DIEGO and TORONTO, July 21, 2020 GLOBE NEWSWIRE -- Aptose Biosciences Inc. Nasdaq: APTO; TSX: APS, a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will release its financial results for the quarter ended June 30, 2020, on Tuesday, August 4, 2020, after the close of the market.Conference Call Webcast: Date:Tuesday, August 4, 2020 Time:5:00 PM EDT Dial In - Toll-Free:1 844-882-7834 Dial In - International:1 574-990-9707 Passcode:8367033 Webcast:LINK Replay available through August 11, 2020: Dial In - Toll-Free: 1 855-859-2056 Dial In - International: 1 404-537-3406 Replay Passcode:8367033 The live conference call can also be accessed through a link on the Investor Relations section of Aptoses website at An archived version of the webcast along with a transcript will be available on the companys website for 30 days.The press release, the financial statements and the managements discussion and analysis for the quarter ended June 30, 2020 will be available on SEDAR at and EDGAR at Aptose Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The Companys small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage investigational products for hematologic malignancies: CG-806, an oral, first-in-class mutation-agnostic FLT3BTK kinase inhibitor, is in a Phase 1 trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia CLL, small lymphocytic lymphoma SLL and non-Hodgkin lymphoma NHL, who have failed or are intolerant to standard therapies, and has received an IND allowance to conduct a separate Phase 1 trial in patients with relapsed or refractory acute myeloid leukemia AML; APTO-253, the only clinical stage agent that directly targets the MYC oncogene and suppresses its expression, is in a Phase 1b clinical trial for the treatment of patients with relapsed or refractory acute myeloid leukemia AML or high risk myelodysplastic syndrome MDS.For further information, please contact: Aptose Biosciences Inc.LifeSci Advisors, LLC Greg ChowDan Ferry, Managing Director Executive Vice President, CFO617-535-7746 SMP Communications Susan Pietropaolo 201-923-2049 